Literature DB >> 20665209

Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.

William W Stoops1, Kevin W Hatton, Michelle R Lofwall, Paul A Nuzzo, Sharon L Walsh.   

Abstract

RATIONALE: Nonmedical use and abuse of prescription opioids is an increasing public health problem. Intravenous (IV) administration of opioid analgesics intended for oral use is not uncommon; yet, little is known about the relative abuse potential of these drugs when administered intravenously to recreational opioid abusers without physical dependence.
METHODS: This inpatient study employed a double-blind, randomized, within-subject, placebo-controlled design to examine the relative abuse potential of IV doses of oxycodone, hydrocodone, and morphine. Nine healthy adult participants reporting recreational opioid use and histories of IV opioid use completed 11 experimental sessions, including one active-dose practice session. IV doses were infused over 5 min and included three identical doses of each opioid (5, 10, and 20 mg/10 ml) and saline placebo. Physiological, subjective, and performance effects were collected before and for 6 h after drug administration.
RESULTS: All three opioids produced prototypical mu agonist effects (e.g., miosis; increased ratings of liking) that were generally dose-related. Pharmacodynamic effects were observed within 5 min of IV administration. Physiological effects were more prolonged than subjective effects for all three drugs. While the magnitude of effects was generally comparable across drugs and qualitatively similar, valid potency assays indicated the following potency relationship: oxycodone > morphine > hydrocodone.
CONCLUSIONS: There were modest potency differences between oxycodone, hydrocodone, and morphine, but their overall profile of effects was similar, indicating significant abuse potential when administered intravenously.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20665209      PMCID: PMC2939200          DOI: 10.1007/s00213-010-1942-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  31 in total

1.  The reinforcing and subjective effects of morphine in post-addicts: a dose-response study.

Authors:  R J Lamb; K L Preston; C W Schindler; R A Meisch; F Davis; J L Katz; J E Henningfield; S R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1991-12       Impact factor: 4.030

2.  Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.

Authors:  James P Zacny
Journal:  Psychopharmacology (Berl)       Date:  2002-10-29       Impact factor: 4.530

3.  Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.

Authors:  W R Martin; J W Sloan; J D Sapira; D R Jasinski
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Assessment of the dependence-producing properties of dihydrocodeinone and codoxime.

Authors:  D R Jasinski; W R Martin
Journal:  Clin Pharmacol Ther       Date:  1967 Mar-Apr       Impact factor: 6.875

5.  Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans.

Authors:  M E Abreu; G E Bigelow; L Fleisher; S L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2001-02       Impact factor: 4.530

6.  Psychomotor, respiratory and neuroendocrinological effects of a mu-opioid receptor agonist (oxycodone) in healthy volunteers.

Authors:  U Saarialho-Kere; M J Mattila; T Seppälä
Journal:  Pharmacol Toxicol       Date:  1989-10

7.  Kinetics of intravenous and intramuscular morphine.

Authors:  D R Stanski; D J Greenblatt; E Lowenstein
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

8.  Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.

Authors:  Lon Hays; Kenneth L Kirsh; Steven D Passik
Journal:  J Natl Compr Canc Netw       Date:  2003-07       Impact factor: 11.908

9.  Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2003-08-29       Impact factor: 4.530

10.  Comparison of intravenously administered methadone, morphine and heroin.

Authors:  D R Jasinski; K L Preston
Journal:  Drug Alcohol Depend       Date:  1986-07       Impact factor: 4.492

View more
  31 in total

1.  Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis.

Authors:  April M Young; Jennifer R Havens
Journal:  Addiction       Date:  2011-10-26       Impact factor: 6.526

2.  Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users.

Authors:  William W Stoops; Paul E A Glaser; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2013-02-21       Impact factor: 4.530

3.  Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Drug Alcohol Depend       Date:  2012-02-25       Impact factor: 4.492

4.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

5.  The opioid rotation ratio of hydrocodone to strong opioids in cancer patients.

Authors:  Akhila Reddy; Sriram Yennurajalingam; Hem Desai; Suresh Reddy; Maxine de la Cruz; Jimin Wu; Diane Liu; Eden Mae Rodriguez; Jessica Waletich; Seong Hoon Shin; Vicki Gayle; Pritul Patel; Shalini Dalal; Marieberta Vidal; Kimberson Tanco; Joseph Arthur; Kimmie Tallie; Janet Williams; Julio Silvestre; Eduardo Bruera
Journal:  Oncologist       Date:  2014-10-23

6.  Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2011-12-30       Impact factor: 4.492

7.  Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Authors:  Sandra D Comer; Verena E Metz; Ziva D Cooper; William J Kowalczyk; Jermaine D Jones; Maria A Sullivan; Jeanne M Manubay; Suzanne K Vosburg; Mary E Smith; Deena Peyser; Phillip A Saccone
Journal:  Behav Pharmacol       Date:  2013-09       Impact factor: 2.293

8.  Oxycodone-Mediated Activation of the Mu Opioid Receptor Reduces Whole Brain Functional Connectivity in Mice.

Authors:  Md Taufiq Nasseef; Jai Puneet Singh; Aliza T Ehrlich; Michael McNicholas; Da Woon Park; Weiya Ma; Praveen Kulkarni; Brigitte L Kieffer; Emmanuel Darcq
Journal:  ACS Pharmacol Transl Sci       Date:  2019-06-28

9.  Abuse liability and reinforcing efficacy of oral tramadol in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Anthony J Siegel; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2012-10-23       Impact factor: 4.492

10.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.